Brian Higgins
Impact in
- Oncology top 5%
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
-
- Monoclonal and Polyclonal Antibodies Research
Papers in
- Genetics 6
- Myeloproliferative Neoplasms: Diagnosis and Treatment 5
-
- Chronic Myeloid Leukemia Treatments 4
- Acute Myeloid Leukemia Research 3
- Co-authors
- David B. Agus (8 shared papers)Howard I. Scher (8 shared papers)Carlos Cordon‐Cardo (6 shared papers)William D. Fox (5 shared papers)Mark X. Sliwkowski (2 shared papers)Robert W. Akita (2 shared papers)Julie A. Lofgren (2 shared papers)Lisa M. Butler (2 shared papers)
- Journals
- Bioorganic & Medicinal Chemistry Letters (2 papers)Haematologica (2 papers)Blood (2 papers)Cancer Cell (1 paper)JAMA Network Open (1 paper)
- Partner nations
- United StatesSwitzerlandUnited Kingdom
In The Last Decade
Brian Higgins
20 papers receiving 2.2k citations
Brian Higgins's Hit Papers
Peers
Comparison fields: 5 of 91
- Oncology 955
- Radiology, Nuclear Medicine and Imaging 479
- Molecular Biology 1.4k
- Pulmonary and Respiratory Medicine 456
- Cancer Research 188
Countries citing papers authored by Brian Higgins
This map shows the geographic impact of Brian Higgins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Higgins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Higgins more than expected).
Fields of papers citing papers by Brian Higgins
This network shows the impact of papers produced by Brian Higgins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Higgins. The network helps show where Brian Higgins may publish in the future.
Co-authors
The 25 scholars most cited alongside Brian Higgins, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth Hit paper breakdown → | 2002 | 746 |
| 2 | Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. | 2000 | 547 |
| 3 | 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. | 2002 | 373 |
| 4 | Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. | 2000 | 132 |
| 5 | Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. | 1999 | 125 |
| 6 | Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. | 2001 | 108 |
| 7 | Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. | 2002 | 91 |
| 8 | A potential role for activated HER-2 in prostate cancer. | 2000 | 37 |
| 9 | 2010 | 33 | |
| 10 | 2010 | 25 | |
| 11 | Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model. | 2007 | 23 |
| 12 | 2023 | 16 | |
| 13 | Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts. | 2009 | 16 |
| 14 | 2010 | 12 | |
| 15 | 2006 | 10 | |
| 16 | 2024 | 10 | |
| 17 | 2020 | 9 | |
| 18 | 2024 | 2 | |
| 19 | 2024 | 2 | |
| 20 | 2020 | 1 |
About Brian Higgins
Brian Higgins is a scholar working on Genetics, Hematology, Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 21 papers that have together received 2.3k indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers), Chronic Myeloid Leukemia Treatments (4 papers), Acute Myeloid Leukemia Research (3 papers), HER2/EGFR in Cancer Research (3 papers), Kruppel-like factors research (3 papers), Ubiquitin and proteasome pathways (3 papers), Peptidase Inhibition and Analysis (2 papers) and Prostate Cancer Treatment and Research (2 papers). The work is most often cited by research in Oncology (955 citations), Radiology, Nuclear Medicine and Imaging (479 citations), Molecular Biology (1.4k citations), Pulmonary and Respiratory Medicine (456 citations) and Cancer Research (188 citations). Brian Higgins has collaborated with scholars based in United States, Switzerland and United Kingdom. Frequent co-authors include David B. Agus, Howard I. Scher, Carlos Cordon‐Cardo, William D. Fox, Mark X. Sliwkowski, Robert W. Akita, Julie A. Lofgren, Lisa M. Butler, Douglas P. Evans and Victoria M. Richon. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Haematologica, Blood, Cancer Cell and JAMA Network Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.